Clinical Trial Update: Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer [Phase 3]

View source ↗

Summary

This Phase 3 trial is evaluating adding pembrolizumab to standard radiation therapy for newly diagnosed early-stage high-intermediate risk endometrial cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Endometrial Endometrioid Adenocarcinoma, Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 | Phase 3 | Status: ACTIVE_NOT_RECRUITING